Literature DB >> 2911842

Interaction between digoxin and propafenone.

M V Calvo1, A Martin-Suarez, C Martin Luengo, C Avila, M Cascon, A Domínguez-Gil Hurlé.   

Abstract

The pharmacokinetic and pharmacodynamic interactions between digoxin and propafenone were investigated in 10 hospitalized patients with heart disease and cardiac arrhythmias. During steady state (0.25 mg/day) the glycoside was combined with 600 mg of propafenone daily for 1 week. The mean +/- SD serum digoxin concentration (SDC) was 0.97 +/- 0.29 ng/ml before and 1.54 +/- 0.65 ng/ml (p less than 0.003) during propafenone administration. Propafenone induced a mean decrease in 31.1 and 31.7% in total and renal digoxin clearances, respectively. The increase in SDCs was accompanied by a decrease in heart rate (HR) and shortening of QTC (QT interval corrected for HR). In patients receiving digoxin and propafenone simultaneously, the SDCs should be monitored and the digoxin dose reduced if there is evidence of toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2911842     DOI: 10.1097/00007691-198901000-00003

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  7 in total

1.  Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.

Authors:  Iouri Bachmakov; Sabine Rekersbrink; Ute Hofmann; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-15       Impact factor: 3.000

2.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Authors:  B Greiner; M Eichelbaum; P Fritz; H P Kreichgauer; O von Richter; J Zundler; H K Kroemer
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

Review 3.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 4.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

5.  Successful treatment of propafenone, digoxin and warfarin overdosage with plasma exchange therapy and rifampicin.

Authors:  Sule Unal; Benan Bayrakci; Umit Yasar; Tevfik Karagoz
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumours.

Authors:  Mohamed Elmeliegy; István Láng; Elena A Smolyarchuk; Chin-Hee Chung; Anna Plotka; Haihong Shi; Diane Wang
Journal:  Br J Clin Pharmacol       Date:  2020-01-07       Impact factor: 4.335

Review 7.  Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.

Authors:  Mohamed Elmeliegy; Manoli Vourvahis; Cen Guo; Diane D Wang
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.